Last reviewed · How we verify
NCT04753671: QUANTRA®_GPP
QUANTRA® References Range Protocol in Pregnancy and Postpartum
trial in Pregnancy Postpartum in 31 participants. Completed in 7 November 2022.
7 November 2022
Quick facts
| Lead sponsor | University Hospital, Lille |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 31 |
| Start date | 5 May 2021 |
| Primary completion | 7 November 2022 |
| Estimated completion | 7 November 2022 |
| Sites | 1 location across France |
Conditions studied
- Pregnancy Postpartum — all drugs for Pregnancy Postpartum →
Sponsor
University Hospital, Lille
Who can join
18 and older, female only, with Pregnancy Postpartum. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Postpartum hemorrhage (PPH) remains the leading cause of maternal death. PPH associated coagulopathy varies and their treatments (tranexamic acid, fibrinogen concentrates,plasma, platelets need to be targeted and administrated early. Point of care hemostasis devices are helpful to develop this strategy. Quantra® (STAGO BIOCARE) use an innovative method to detect the clot formation. Pregnancy and non-hemorrhagic postpartum reference ranges are missing. The objective of this study is to establish these norms needed to elaborate thereafter the thresholds to be targeted in PPH conditions.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Peri-partum reference range for the point-of-care viscoelastic testing device Quantra® QStat in healthy pregnancy and non-haemorrhagic post-partum - A short communication.
Lukowiak O, Le Gouez A, Djebbour M, Mercier FJ, et al · · 2025 · cited 1× · PMID 40252700 · DOI 10.1016/j.accpm.2025.101521
Verify or expand the search:
- PubMed search for NCT04753671
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other University Hospital, Lille trials
Trials by the same sponsor.
- NCT07528664 — Assessement of a Test a Financial-incentive Program for Pregnant Women and Their Smoking Partners to Reduce Smoking Duri · NA · not yet recruiting
- NCT07434739 — PAravertebral CaTheter Versus Epidural Analgesia in Totally Minimally Invasive Esophagectomies · NA · not yet recruiting
- NCT06958224 — Theranostic Approach by Early Multigene Sequencing in Advanced Poor Prognosis Cancers · NA · not yet recruiting
- NCT07408999 — Totally Versus Hybrid Minimally Invasive Esophagectomy for Esophageal Cancer · NA · not yet recruiting
- NCT07492030 — Validation of the Use of the Arteriovenous Tension Difference in CO2 Under Hyperbaric Conditions · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04753671 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University Hospital, Lille
- Last refreshed: 26 December 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04753671.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing